PharmaCyte Net Debt vs Accounts Payable Analysis
| PMCB Stock | USD 1.62 0.05 2.99% |
PharmaCyte Biotech financial indicator trend analysis is much more than just breaking down PharmaCyte Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PharmaCyte Biotech is a good investment. Please check the relationship between PharmaCyte Biotech Net Debt and its Accounts Payable accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.
Net Debt vs Accounts Payable
Net Debt vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PharmaCyte Biotech Net Debt account and Accounts Payable. At this time, the significance of the direction appears to have almost no relationship.
The correlation between PharmaCyte Biotech's Net Debt and Accounts Payable is 0.17. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of PharmaCyte Biotech, assuming nothing else is changed. The correlation between historical values of PharmaCyte Biotech's Net Debt and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of PharmaCyte Biotech are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Debt i.e., PharmaCyte Biotech's Net Debt and Accounts Payable go up and down completely randomly.
Correlation Coefficient | 0.17 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Accounts Payable
An accounting item on the balance sheet that represents PharmaCyte Biotech obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of PharmaCyte Biotech are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from PharmaCyte Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PharmaCyte Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 122.83, whereas Selling General Administrative is forecasted to decline to about 4.8 M.
PharmaCyte Biotech fundamental ratios Correlations
Click cells to compare fundamentals
PharmaCyte Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PharmaCyte Biotech fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 816.6K | 552.5K | 499.0K | 400.2K | 6.7M | 7.0M | |
| Total Current Liabilities | 1.0M | 724.8K | 704.4K | 586.6K | 7.4M | 7.8M | |
| Total Stockholder Equity | 5.1M | 6.7M | 89.9M | 72.7M | 39.5M | 41.5M | |
| Retained Earnings | (103.9M) | (107.4M) | (111.6M) | (116.0M) | (115.6M) | (109.8M) | |
| Common Stock Total Equity | 101.3K | 118.6K | 163.9K | 159.0 | 182.85 | 173.71 | |
| Common Stock Shares Outstanding | 1.4B | 1.7B | 15.5M | 19.5M | 9.6M | 9.1M | |
| Other Stockholder Equity | 108.8M | (20.4K) | 201.6M | 188.7M | 143.3M | 150.5M | |
| Total Liab | 1.1M | 724.8K | 704.4K | 586.6K | 20.4M | 21.4M | |
| Common Stock | 163.9K | 159.0 | 2.1K | 2.2K | 2.2K | 2.1K | |
| Total Assets | 6.2M | 7.4M | 90.6M | 73.3M | 59.9M | 62.9M | |
| Net Debt | (819.7K) | (2.2M) | (85.4M) | (68.0M) | (50.2M) | (47.7M) | |
| Accounts Payable | 185.8K | 172.3K | 205.4K | 128.3K | 389.4K | 322.7K | |
| Cash | 894.9K | 2.2M | 85.4M | 68.0M | 50.2M | 52.7M | |
| Cash And Short Term Investments | 2.5M | 2.2M | 85.4M | 68.0M | 50.2M | 52.7M | |
| Liabilities And Stockholders Equity | 6.2M | 7.4M | 90.6M | 73.3M | 59.9M | 62.9M | |
| Non Current Liabilities Total | 121.9K | 46.3K | 172.3K | 205.4K | 13.0M | 13.6M | |
| Total Current Assets | 1.0M | 2.3M | 85.5M | 68.1M | 50.4M | 53.0M | |
| Other Current Assets | (1.4M) | 73.1K | 188.3K | 215.4K | 259.8K | 241.3K | |
| Accumulated Other Comprehensive Income | (21.7K) | (20.4K) | (15.8K) | (23.0K) | (23.5K) | (24.7K) | |
| Net Tangible Assets | 1.5M | 1.5M | 3.1M | 86.4M | 99.3M | 104.3M | |
| Net Invested Capital | 5.2M | 6.7M | 89.9M | 72.7M | 27.6M | 30.4M | |
| Net Working Capital | 6.2K | 1.6M | 84.8M | 67.6M | 43.0M | 27.6M | |
| Capital Stock | 163.9K | 159.0 | 2.1K | 2.2K | 11.9M | 12.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PharmaCyte Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PharmaCyte Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacyte Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacyte Biotech Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.64 | Return On Assets (0.05) | Return On Equity 0.4788 |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.